Nusano signs its first commercial radioisotope supply deal with Ratio Therapeutics, accelerating cancer drug development and delivering on promises made at its Utah facility’s opening to reshape U.S. radiopharmaceutical manufacturing.
West Valley City, Utah and Boston, MA — June 17, 2025
Nusano, the West Valley City-based isotope innovator, has secured its first commercial supply agreement since opening its 140,000-square-foot production facility earlier this year. The multi-isotope deal with Boston-based Ratio Therapeutics provides a reliable, high-volume source of isotopes essential to cancer diagnosis and treatment, solidifying Nusano’s emergence as a clinical supply chain player.
“This agreement is the foundation for a strategic alliance aimed at unlocking the full potential of radiopharmaceuticals,” said Chris Lowe, CEO of Nusano. “By collaborating with forward-thinking radiopharmaceutical companies like Ratio, we’re working to meet current clinical needs and support the development of next-generation radiopharmaceuticals.”
At its June 9th VIP preview tour — covered by TechBuzz News — Nusano emphasized its proprietary ion source technology, capable of producing over 40 different isotopes. Company executives, real estate developers and many Utah officials hailed the state-of-the-art facility in West Valley City as a potential national hub for isotope production, poised to fix chronic shortages in medical and industrial supply chains.
That vision is now in motion. The agreement grants Ratio access to copper-64 (Cu-64) for PET imaging, along with therapeutic isotopes lutetium-177 (Lu-177) and actinium-225 (Ac-225). Ratio will use these isotopes in its precision radiopharmaceutical pipeline, which includes a FAP-targeted therapy for soft tissue sarcoma set to enter clinical trials this year.
“We are pleased to enter into this agreement with Nusano, a company whose isotope production platform enables Ratio to secure a critical supply chain advantage. By gaining access to Cu-64 for imaging and Ac-225 for therapies, we can confidently advance our radiopharmaceutical clinical programs,” said Jack Hoppin, Ph.D., Chairman and Chief Executive Officer of Ratio Therapeutics. “Limited supply and high costs of Cu-64 have put significant constraints on its clinical use. By accessing Nusano’s production capabilities, we’re removing a critical bottleneck and enabling broader adoption across the field.”
Ratio recently announced its own 65,000 square foot manufacturing facility not far from Nusano’s West Valley City plant. Ratio has partnered with the Medical Innovation Technology Management division of Wasatch Group to build a state-of-the-art radiopharmaceutical research and manufacturing facility to be fully operational in the second half of 2027. It is the first tenant in the Wasatch Group's Medical Innovation Technology Research and Development Park in West Valley City.
The company’s announcement was the result of collaboration among Jonathan Springmeyer of West Valley City, Doug Cole of NAI Premier, EDCUtah, Wasatch Group, the Governor’s Office of Economic Opportunity, and Kelvyn Cullimore of BioUtah.
Ratio's proximity, combined with Nusano’s scaled production capabilities, minimizes shipping complexity and supports just-in-time delivery — a key requirement for short half-life isotopes like Cu-64.
As TechBuzz reported last week, Nusano’s facility was designed from the ground up for clinical and commercial output, with thick concrete construction, shielded hot cells, GMP compliance, and a proprietary ion beam system that achieves isotope yields and variety beyond traditional cyclotrons or reactors.
“This agreement de-risks our development pipeline,” said Hoppin, “and positions us to deliver innovative radiopharmaceuticals to patients across the U.S. and beyond.”
While this supply deal puts Nusano’s medical mission in the forefront, it’s part of a broader strategy. As TechBuzz revealed on June 12, the company is also entering the nuclear fuel market. Nusano claims a breakthrough in the production of high-assay low-enriched uranium (HALEU), a key fuel for next-generation reactors. The same ion source tech underpinning its medical isotopes is being adapted to support the energy sector — potentially reducing U.S. dependence on foreign HALEU suppliers.
With the Ratio agreement in place, Nusano is delivering on its stated plans shared at its recent VIP preview tour to stabilize a fractured isotope supply landscape; it is now actively supplying front-line cancer researchers.
For more information about Nusano and Ratio Therapeutics, visit nusano.com and ratiotx.com.